Searched for
REVLIMID IMPACT
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh inDr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared w...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Can DRL’s new product launches offset the slowdown in Revlimid sales?Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US...
- Can US generics momentum and CDMO strength keep pharma earnings steady this quarter?Indian pharmaceutical companies are set for a steady September quarter. Growth in the US generics market and domestic sales will drive perf...
- Cipla targets $1 bn US revenue in FY27Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in respiratory generics ...
- Capacity push and new drugs critical for Aurobindo's healthA delay in drug approvals in the US market remains a concern for Aurobindo. The company stated that eight ANDAs (abbreviated new drug appli...
- Dr Reddy’s, Zydus, Cipla, Sun can sustain low-double digit EPS growth over medium term: Bino PathiparampilIndian pharma companies like Dr Reddy’s, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term. The generic Re...
- Dr Reddy's shares rally 4% as Nuvama upgrades rating to buyDr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the impact of Re...
- Dr Reddy's Labs shares up 3% after Q2 results. What should investors do?Dr. Reddy's Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While analysts acknowled...
- ‘Defensive’ pharma scales new peak as Street looks beyond high-growth playsPharma stocks have gained investor interest as the Nifty Pharma index reaches new highs. Amid economic uncertainties, defensive sectors lik...
- Foram Parekh on what to bet on in pharma packForam Parekh shares insights on CDMO companies' positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about L...
- Dr Reddy's shares rise 4% on Q3 PAT jump but brokerages remain unmoved. Here's whyThe drug maker on Tuesday reported an 11% year-on-year (YoY) jump in net profit at Rs 1,379 crore for the quarter ended December 31, 2023, ...
- Sun facing some clouds is still a buy for analystsShares declined nearly 2.5% in Monday's trading before recouping most of its losses. The stock eventually closed at ₹968.50, down 0.14% fro...
- Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommendDr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Th...
- Dr Reddy's Laboratories sees generic Revlimid, other launches to keep US business firingThe Hyderabad-based drug maker on Friday reported its highest ever revenues, largely driven by generic Revlimid launch during the second qu...
- Dispute settlement gives this stock an edge over peers in pharma packKunal Dhamesha of Emkay Global raised his price target for the stock to Rs 1,000 and sees potential gain of Rs 45 per share from the settle...
- DRL faces patent suit in US over allergy genericNYSE-listed Dr Reddy’s Laboratories (DRL) is embroiled in a fresh patent infringement row with US-based drug-discovery firm Albany Molecula...
Load More
